Effective treatment methods for human leukemia are under development, but so far none of them have been found to be completely satisfactory. It was recently reported that palladium complexes have significant anticancer activity as well as lower toxicity compared with some clinically used chemotherapeutics. The anticancer activities of two novel palladium(II) complexes, [Pd(sac)(terpy)](sac)·4H 2 O and [PdCl(terpy)](sac)·2H 2 O, were tested against three human leukemia cell lines, Jurkat, MOLT-4, and THP-1, in comparison with cisplatin and adriamycin. The cytotoxic effect of the drugs was determined using the MTT assay. Cell death was assessed using fluorescein isothiocyanateannexin/propidium iodide staining for flow cytometry. Furthermore, p53 phosphorylation, poly(ADP-ribose) polymerase cleavage, and Bax and Bcl-2 mRNA levels were examined to elucidate the mechanism of cell death induction. Both complexes exhibited a significant dosedependent antigrowth effect in vitro. The complexes predominately induced apoptosis, but necrosis was also observed. In-vitro results have shown that palladium(II) complexes may be regarded as potential anticancer agents for treating human leukemia. Therefore, further analysis to determine the putative mechanism of action and in-vivo studies on animal models are warranted.
Introduction
The treatment of leukemia is in constant flux, evolving and changing rapidly over the past few years. Most treatment protocols use systemic chemotherapy with or without radiotherapy. The basic strategy is to eliminate all detectable disease by using cytotoxic agents. Commonly used cytotoxic drugs include metabolic analogs, glucocorticoids, asparaginase, anthracyclines, and vincristine [1, 2] . Chemotherapeutic agents kill rapidly dividing cells, thus slowing down and stopping the spread of cancerous cells. Anticancer drugs originate from a variety of sources like plants, microbes, or warfare agents. Over the past 30 years, platinum-based drugs, notably cisplatin and carboplatin, have dominated the treatment of various cancers [3] . In recent years, numerous palladium(II) [Pd(II)] complexes have been synthesized and published [4, 5] . It has been shown that Pd complexes have significant antitumor activity to cancer cells as well as lower side effects compared with cisplatin [6] . The aqueous solubility of Pd complexes is better when compared with platinum complexes, making Pd more attractive [7] . Moreover, it is expected that Pd complexes have less kidney toxicity compared with cisplatin [8] .
Ari and colleagues [9] [10] [11] . The anticancer effect of these complexes 1 and 2 tested in vitro presents significant potential as an anticancer agent in the following cancer cell lines: A549 and H1299 for lung cancer; C6 for glioblastoma; Hep3B for liver cancer; PNT1A, PNT2-C2, BPH-1, P4E6, PC-3, and LNCaP for prostate cancer; and MCF-7 and MDA-MB-231 for breast cancer [9, 10, [12] [13] [14] .
Complex 2 was further screened against primary cultures from seven Gleason 6/7 prostate cancer, three Gleason 8/9 prostate cancer, and four benign prostate hyperplasia patient samples, as well as against cancer stem cells selected from primary cultures. It presented considerable antigrowth effect on most primary cultures and inhibited the growth of cancer stem cells [14] . Complex 2 was found to significantly reduce the growth of tumors inoculated into mice, and presented a mild-to-low toxicity profile in vivo [12] .
The interaction of Pd complexes with fish sperm DNA clearly indicated that these complexes act as dualfunction metallointercalators and strongly bind to DNA by both interacalation and coordination [15] . Following Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal's website (www.anti-cancerdrugs.com).
exposure to complex 2, most cancer cell lines undergo apoptotic cell death, whereas cell lines A549, H1299, and PC-3 underwent necrosis [13] . Primary prostate cells induced autophagy following treatment [14] . From published data it can be concluded that Pd complexes have a differential effect on cell death that is dependent on the genetic background of the cells.
Therefore, in the present paper, we investigated the growth-inhibiting effects of complexes 1 and 2 against three different leukemia cell lines -Jurkat and MOLT-4 as models of acute lymphoblastic leukemia and THP-1 as a model of acute monocytic leukemia.
Methods

Culture of cell lines
Human leukemia cell lines Jurkat (human acute T-lymphocyte leukemia), MOLT-4 (human acute T-lymphoblastic leukemia), and THP-1 (human acute monocytic leukemia) were used in this study. Cells were cultured in RPMI 1640 medium (Sigma-Aldrich, St Louis, Missouri, USA) supplemented with penicillin (100 U/ml), streptomycin (100 μg/ml), L-glutamine, and 10% fetal bovine serum (Gibco, Paisley, UK) at 37°C in a humidified atmosphere containing 5% CO 2 . The medium was replaced every 48 h, and cell density was maintained at 10 6 cells/ml.
Chemicals
The drugs used in this study were cisplatin (Sigma-Aldrich), adriamycin (Farmitalia, Milan, Italy), and two novel Pd(II) complexes -[Pd(sac)(terpy)](sac)·4H 2 O (complex 1) and [PdCl(terpy)](sac)·2H 2 O (complex 2). The Pd complexes were synthesized at the Chemistry Department of the Science and Art, Faculty of Uludag University, Turkey, and were kindly provided by Professor Dr Veysel T. Yilmaz. The synthesis, characterization, and crystal structures have been reported previously [11] . Stock concentrations (0.2 mmol/l) of each chemical were prepared in sterile PBS and sterilized by filtration (Millipore, Billerica, Massachusetts, USA). All tests were performed by treating cells with a concentration corresponding to the IC 50 values for each cell line and each chemical.
MTT assay
The cytotoxic effect of chemicals was determined using MTT assay according to the modified protocol of Ulukaya et al. [16] . Before the assay, a stock solution of MTT (Sigma-Aldrich) was prepared (5 mg/ml PBS, pH 7.2). Cells were seeded at a density of 5000 cells/well in a 96-well plate in triplicate and grown in MEM medium (Sigma-Aldrich) supplemented with penicillin (100 U/ml), streptomycin (100 μg/ml), L-glutamine, and 10% fetal bovine serum (Gibco), without phenol-red dye.
Cells were treated for 72 h with 0.1, 0.2, 0.4, 0.8, 1.6, 3.2, 6.4, 12.8, 25.6, and 51.2 μmol/l of each chemical. After the incubation period, 25 μl of MTT stock solution was added to each well, and then after another 4 h incubation at 37°C 100 μl of solubilizing buffer (10% SDS dissolved in 0.01 N HCl) was added to each well. Cells were incubated overnight at 37°C. The absorbance at 570 nm was measured using a microplate reader (Labsystems Multiscan MS; Thermo Electron Corp., Vantaa, Finland). Untreated control cell lines were defined as 100% viable. Viability of treated cells was calculated as follows:
Detection of annexin V-positive cells using flow cytometry
Cell death, following treatment, was determined using fluorescein isothiocyanate (FITC)-annexin V Dead Cell Apoptosis Kit (Invitrogen, Carlsbad, California, USA). The kit is designed to discriminate living cells from those in the stage of early apoptosis or late apoptosis/secondary necrosis.
Following drug treatment, cells were washed twice in icecold PBS and centrifuged for 5 min at 800g at 4°C. They were resuspended in annexin binding buffer (10 mmo/l HEPES, 140 mmol/l NaCl, 2.5 mmol/l CaCl 2 , pH 7.4) to a final concentration of 2 × 10 6 cells/100 μl. Aliquots containing 2 × 10 6 cells in 100 μl of buffer were stained with 5 μl of FITC-annexin V [solution in 25 mmol/l HEPES, 140 mmol/l NaCl, 1 mmol/l EDTA, pH 7.4, 0.1% BSA] and 1 μl of propidium iodide (100 μg/ml in annexin binding buffer) for 15 min in the dark at room temperature. After staining, 400 μl of annexin binding buffer was added to the cells and samples were analyzed by flow cytometry within 1 h (FACScalibur; Becton Dickinson). Data analyses were performed using FACS Diva analysis software (BD BioSciences, Franklin Lakes, New Jersey, USA). Excitation was at 488 nm with an emission wavelength of 530 nm for green (fluorescein) fluorescence and 580 nm for red (propidium iodide) fluorescence.
Total protein extraction and quantification
Following treatment, cells were collected, washed twice in ice-cold PBS, and centrifuged for 5 min at 1000g, 4°C. 
Statistical analysis
All results are presented as mean SD. Significant differences between groups were evaluated by means of Student's t-test (P < 0.05).
Results
Growth-inhibiting effects of the complexes, cisplatin, and adriamycin
The antigrowth effects of complexes 1 and 2, cisplatin, and adriamycin on leukemia cell lines (Jurkat, MOLT-4, and THP-1) were evaluated using the MTT assay after treating cells with different concentrations of the tested compounds for 72 h.
Both Pd complexes significantly inhibited the growth of leukemia cells in a dose-dependent manner (Fig. 1) . However, the extent of cell sensitivity to the tested compounds varied among the cell lines used. Adriamycin was found to be superior in all three leukemia cell lines, whereas cisplatin was the least effective in Jurkat and THP-1 cell lines. Jurkat and MOLT-4 cell lines were equally sensitive to complexes 1 and 2, whereas the THP-1 cell line was more sensitive to complex 1 than to complex 2.
Following the MTT assay, IC 50 values were calculated (Table 1) . For the Jurkat and THP-1 cell lines, IC 50 values of complexes 1 and 2 were between IC 50 values of cisplatin and adriamycin, presenting better antigrowth effect compared with platinum-based cisplatin. IC 50 values for complexes 1 and 2 for the MOLT-4 cell line were the highest.
Determination of cell death using annexin V staining
The cell death-inducing effects of complexes 1 and 2, cisplatin, and adriamycin were evaluated by flow cytometry to detect phosphatidylserine on the outer membrane of cells marking apoptosis. Jurkat, MOLT-4, and THP-1 cell lines were treated with a compound concentration of IC 50 value. The treatments resulted in cell death induction in all cell lines (Fig. 2) . The Jurkat cell line presented the best apoptotic response to cisplatin and adriamycin. The viability was decreased after treatment with Pd complexes, and apoptosis was the dominant type of cell death. The MOLT-4 cell line presented the best apoptotic response to adriamycin. The viability was very low after treatment with Pd complexes. Apoptosis was the dominant type of cell death, but the level of secondary necrosis was also significant. The THP-1 cell line presented the best response to adriamycin and complex 2, and the cell death included apoptosis and secondary necrosis (see Figure, Supplemental digital content 2, http://links.lww.com/ACD/ A84 showing flow cytometry analysis).
Apoptosis induction through the intrinsic pathway
Apoptosis is activated through the phosphorylation of p53, which signals DNA damage. Phosphorylation of p53 is present and induced in all three leukemia cell lines after treatment with complexes 1 and 2, cisplatin, and adriamycin. The MOLT-4 cell line was treated with the highest concentrations of drugs corresponding to IC 50 values, causing quick cell death and protein degradation, which was judged by the disappearance of the full-length PARP-1 bands.
The executor of apoptosis is caspase 3, the protease that cleaves PARP-1 among other substrates. Therefore, cleavage of PARP-1 is a marker of apoptosis. PARP-1 was cleaved following treatment in all three leukemia cell lines; however, the extent was different (Fig. 3 ). The Jurkat cell line showed slight amount of cleavage after treatment with complexes 1 and 2. The MOLT-4 cell line showed full-length PARP-1 protein degradation possibly due to high concentrations of complexes 1 and 2.
The THP-1 cell line showed slight PARP-1 cleavage after treatment with cisplatin and complex 1 and extensive PARP-1 degradation after treatment with adriamycin and complex 2.
Changes in mRNA levels of two genes of the Bcl-2 family were simultaneously analyzed, Bax as a proapoptotic and Bcl-2 as an antiapoptotic member, to elucidate the cell death pathway (Fig. 4 ). The Jurkat cell line responded to classical treatments, to cisplatin, and to adriamycin, with increased levels of both Bax and Bcl-2, whereas treatment with complex 1 resulted in an increase in Bax and decrease in Bcl-2 (Fig. 4a) .
Treatment of the THP-1 cell line with any of the drugs/ complexes did not result in significant changes in gene expressions because the change did not occur two-fold or higher (Fig. 4b) . Treatment of the MOLT-4 cell line with adriamycin and complex 1 resulted in an ideal response, which is characterized by an increase in Bax and decrease in Bcl-2. However, neither cisplatin nor complex 2 showed such an effect (Fig. 4c ).
Discussion
In this study, the cytotoxic activity of two novel Pd(II) complexes, which seem to be promising anticancer complexes against solid tumors, has been determined.
These complexes were previously studied on some solid tumors as explained in the previous sections of this paper and satisfactory results were reported [10, [12] [13] [14] . Therefore, we suspected their similarly potent activities against leukemic malignancies. In fact, we obtained promising results for these malignancies. Adriamycin, which is one of the classical drugs used for the treatment of leukemic malignancies, was used as a reference drug to compare the results with these complexes [17] . Cisplatin, a platinum-based compound, with DNA intercalating mechanism of anticancer action, similar to a platinumbased compound, was used as another reference drug [18] . In particular, complex 1 yielded comparable results with adriamycin in two cell lines, Jurkat and THP-1. The IC 50 values were similar to each other in these tumor types (Table 1) . It was 0.08 and 0.05 for adriamycin and 0.14 and 0.06 for complex 1 in Jurkat and PTH-1 cells, respectively. These results warrant complex 1 for further in-vivo analysis.
Further, the mode of cell death was studied using flow cytometry (Fig. 2) . In these two cell lines, early apoptosis was induced by both adriamycin and complex 1, but the amplitude of the increase was better in adriamycin than in complex 1, which shows that complex 1 might induce other types of cell death as well. In fact, in Jurkat cells the cleavage of PARP-1 was more pronounced compared with THP-1 cells. In THP-1 cells (as well as in MOLT-4 cells), full-length PARP-1 actually almost disappeared possibly because of high protein degradation by the complexes, especially by complex 2 in MOLT-4 cells. This may be explained by the effect of complex 2 on autophagy that is a process of macromolecule degradation in cells. Ulukaya et al. [14] showed that complex 2 also induced autophagy in prostate cancer cells.
In terms of the mechanism of action, mitochondria seem to play a role in the cytotoxic activity of these complexes. For example, it was found that complex 1 increased the ratio of Bax/Bcl-2 in Jurkat cells as well as in MOLT-4 cells (Fig. 4) . The increase in this ratio is a well-known action in apoptosis [19] . In fact, PARP-1 cleavages confirm apoptosis in Jurkat cells as well as the presence of the DNA damage-activated Ser15-phosphorylated form of p53 [20, 21] . The similar PARP-1 and p53 pattern was present in MOLT-1 and THP-1 cell lines ( Fig. 3 ).
Taken together, it seems that complexes 1 and 2 have comparable and promising activities with the classical antileukemic drug adriamycin and the similar platinumbased drug cisplatin. Therefore, in-vivo experiments are warranted.
